Cardiac amyloidosis future or investigational therapies
Cardiac amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cardiac amyloidosis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Cardiac amyloidosis future or investigational therapies |
FDA on Cardiac amyloidosis future or investigational therapies |
CDC onCardiac amyloidosis future or investigational therapies |
Cardiac amyloidosis future or investigational therapies in the news |
Blogs on Cardiac amyloidosis future or investigational therapies |
Risk calculators and risk factors for Cardiac amyloidosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
New therapies targeting the serum amyloid protein (SAP), which is an excellent immunogen and a universal component of all amyloid deposits, using monoclonal antibodies are currently being investigated.
Future and Investigational Therapies
Possible future treatment options which are currently being investigated include:
- Anti-SAP antibody
- CPHPC